The New Economy

April 02, 2015 10:58 ET

NeoStem and Immunotherapy: Fighting Cancer from Within

LONDON, ENGLAND--(Marketwired - April 2, 2015) - Immunotherapies work in such a way that they fight diseases by using components of a patient's own immune system, and developments in the field are proving important in the treatment of cancer. In the new issue of The New Economy, David J Mazzo of NeoStem explains how the company is currently teaching patients' immune systems to recognise the cancer or tumour-initiating cells found in patients' specific tumours.

"We believe our unique focus on targeting the tumour-initiating 'stem' cells within a tumour, combined with an innovative business model that consists of a rich cell therapy pipeline, externally recognised manufacturing expertise, and initiatives intended to use innovation to solve the challenges specific to the cell therapy industry, puts NeoStem in the unique position of simultaneously taking part in and shaping the future of cancer immunotherapy," says Mazzo in The New Economy feature.

Speaking on the different groups of immunotherapy available to patients, The New Economy report expands on the challenges associated with the treatment and how the cost of developing autologous treatments can be prohibitive. However, Mazzo goes on to write about the work being done at NeoStem to break down the barriers to entry and what is required if immunotherapy is to become more readily available.

To read the report on NeoStem and a range of other stories in the areas of technology, energy, business and strategy, read the new issue of The New Economy, available in print, on mobile and online now.

World News Media is a leading publisher of quality financial and business magazines, enjoying a global distribution network that includes subscriber lists of the most prominent and senior decision-makers around the world, as well as comprehensive airport, hotel and conference site distribution.

Contact Information

  • For further media information contact:
    The New Economy
    Matthew Timms
    Editorial Department
    +44 (0)20 7553 4177